Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03729778 · ClinicalTrials.gov registry record · Early Phase 1
Impact of HIV-1 and Aging on Mucosal Vaccine Responses
A Early Phase 1 study of HIV Infections and HIV-1-infection, sponsored by VA Eastern Colorado Health Care System.
- Active
- Registry status
- Early Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT03729778: Active Early Phase 1 study of HIV Infections and HIV-1-infection, sponsored by VA Eastern Colorado Health Care System.
NCT03729778 is a Early Phase 1 study of HIV Infections and HIV-1-infection that is active but no longer recruiting, run by VA Eastern Colorado Health Care System. The registered enrollment target is 100 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03729778, a Early Phase 1 study of HIV Infections and HIV-1-infection, is active but no longer recruiting, sponsored by VA Eastern Colorado Health Care System.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
Primary Outcome
Determine pneumococcal specific IgG levels in BAL fluid and NPF and to standardize the results we will compare it to the total levels in the BAL/NPF fluid collected at all timepoints
Conditions Studied
Interventions
- BIOLOGICAL Prevnar-13
Study Locations (1)
Colorado
- Rocky Mountain Regional VA Medical Center - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2028-01-01 |
| Phase | Early Phase 1 |
What the registry record for NCT03729778 still lists
NCT03729778 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (78% lower).
The record links to 4 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Prevnar-13 is the first listed.
NCT03729778 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03729778 about?
NCT03729778 is a clinical study titled "Impact of HIV-1 and Aging on Mucosal Vaccine Responses". The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
What is the current status of trial NCT03729778?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 100 participants. The study started on 2017-01-18. Estimated completion is 2028-01-01.
What conditions does trial NCT03729778 study?
This clinical trial studies the following conditions: HIV Infections, HIV-1-infection, HIV/AIDS, Human Immunodeficiency Virus.
What interventions are being tested in trial NCT03729778?
The interventions under investigation include: Prevnar-13 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03729778?
This trial is sponsored by VA Eastern Colorado Health Care System, which has 42 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03729778 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03729778's enrollment target sits among peer trials
100 267th of 542 higher than 267 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Neuroinflammation FNOS PET/CT in HIV (+) and (-) Subjects With OUD and Healthy Controls
ACTIVE NOT RECRUITING · Early Phase 1
-
Proof-of-Concept Clinical Pharmacology Trial for HIV Antigen Presentation Therapeutic Biologic Mix
ACTIVE NOT RECRUITING · Early Phase 1
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
CAR-T Cells for HIV Infection
RECRUITING · Phase 1
-
A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in People Living With HIV
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI